



# Cigna Corporation (CI)

Updated August 7<sup>th</sup>, 2023 by Nathan Parsh

## Key Metrics

|                             |       |                                            |       |                                  |              |
|-----------------------------|-------|--------------------------------------------|-------|----------------------------------|--------------|
| <b>Current Price:</b>       | \$287 | <b>5 Year CAGR Estimate:</b>               | 13.7% | <b>Market Cap:</b>               | \$85 billion |
| <b>Fair Value Price:</b>    | \$321 | <b>5 Year Growth Estimate:</b>             | 10.0% | <b>Ex-Dividend Date:</b>         | 09/05/2023   |
| <b>% Fair Value:</b>        | 89%   | <b>5 Year Valuation Multiple Estimate:</b> | 2.3%  | <b>Dividend Payment Date:</b>    | 09/21/2023   |
| <b>Dividend Yield:</b>      | 1.7%  | <b>5 Year Price Target</b>                 | \$517 | <b>Years Of Dividend Growth:</b> | 3            |
| <b>Dividend Risk Score:</b> | B     | <b>Retirement Suitability Score:</b>       | C     | <b>Rating:</b>                   | Buy          |

## Overview & Current Events

Cigna is a leading provider of insurance products and services. The company's products include dental, medical, disability and life insurance that it provides through employer-sponsored, government-sponsored and individual coverage plans. Cigna operates four business segments, including Evernorth, which provides pharmacy services and benefit management, U.S. Medical, which provides commercial and government health insurance, International Markets and Group Disability. Evernorth contributes 70% of annual revenues while Cigna Healthcare accounts for 24%. Cigna has annual revenues of ~\$190 billion.

On February 3<sup>rd</sup>, 2023, Cigna announced that it was increasing its quarterly dividend 9.8% to \$1.23.

On August 3<sup>rd</sup>, 2023, Cigna announced second quarter results for the period ending June 30<sup>th</sup>, 2023. For the quarter, revenue grew 6.8% to \$48.6 billion, which was \$1.41 billion more than expected. Adjusted earnings-per-share of \$6.13 compared to adjusted earnings-per-share of \$6.20 in the prior year, but was \$0.09 above estimates.

For the quarter, total pharmacy customers grew 4.1% to 98.7 million. Total medical customers grew 9.5% year-over-year to 19.5 million. Adjusted revenue for the Evernorth segment, which is the largest within the company, increased 9.6% to \$38.2 billion due to organic growth in specialty and care delivery services and management solutions. Adjusted revenue for Cigna Healthcare was up 12.2% to \$12.7 billion due to customer growth and premium rate increases.

Cigna provided an updated outlook for 2023 as well. Revenue is now expected to be least \$190 billion this year, up from \$188 billion previously. The company still forecasts adjusted earnings-per-share of at least \$24.70 for the year.

## Growth on a Per-Share Basis

| Year                      | 2013   | 2014   | 2015   | 2016   | 2017    | 2018    | 2019    | 2020    | 2021    | 2022    | 2023           | 2028           |
|---------------------------|--------|--------|--------|--------|---------|---------|---------|---------|---------|---------|----------------|----------------|
| <b>EPS</b>                | \$6.78 | \$7.43 | \$8.66 | \$8.10 | \$10.46 | \$14.22 | \$17.05 | \$18.45 | \$20.47 | \$23.27 | <b>\$24.70</b> | <b>\$39.78</b> |
| <b>DPS</b>                | \$0.04 | \$0.04 | \$0.04 | \$0.04 | \$0.04  | \$0.04  | \$0.04  | \$0.04  | \$4.00  | \$4.48  | <b>\$4.92</b>  | <b>\$6.28</b>  |
| <b>Shares<sup>1</sup></b> | 279    | 264    | 257    | 257    | 244     | 381     | 373     | 355     | 327     | 305     | <b>296</b>     | <b>285</b>     |

Earnings-per-share have a compound annual growth rate of 13.1% for the 2013 through 2022 period of time. An increase in the share count during this time hides the fact that net profit has actually increased at a rate of almost 16% per year. Cigna's growth rate has remained strong in the medium-term as earnings-per-share have a compound annual growth rate of 10.4% since 2018. One reason that earnings have a CAGR in the double-digit range is that the need for pharmacy services and health care plans will increase as more people age. Cigna's merger with Express Scripts, one of the top pharmacy benefit managers in the market, in 2018 should also provide tailwinds. In addition, Cigna has an ambitious goal to reduce its health care costs, which, overall, have risen much higher than inflation. We reaffirm our targeted earnings-per-share growth rate of 10% through 2028 as we find Cigna's business model very attractive.

Cigna's dividend had never been a priority for the company. After cutting its dividend by 20% in 2009, the company has paid the same amount every year up until 2020. It should be noted that Cigna had typically paid an annual dividend in April of each year. That all changed when the company declared a \$1.00 quarterly dividend for the March 25<sup>th</sup>, 2021

<sup>1</sup> Share count in millions

Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



# Cigna Corporation (CI)

Updated August 7<sup>th</sup>, 2023 by Nathan Parsh

payment date. The company followed that up with a double-digit increase in 2022. We now anticipate dividend growth of at least 5% annually through 2028.

## Valuation Analysis

| Year      | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | Now  | 2028 |
|-----------|------|------|------|------|------|------|------|------|------|------|------|------|
| Avg. P/E  | 10.6 | 12.1 | 15.5 | 16.4 | 16.3 | 13.3 | 10.1 | 10.2 | 11.2 | 14.2 | 11.6 | 13.0 |
| Avg. Yld. | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 1.7% | 1.4% | 1.7% | 1.2% |

Shares of Cigna have increased \$36, or 14.3%, since our May 22<sup>nd</sup>, 2023 report. The stock has an average price-to-earnings ratio of 13.0 over the last decade. Currently, the stock is valued at 11.6 times earnings estimates for the year. Price-to-earnings ratios were likely lower during the early portions of the past decade due to market concerns over how health care plans would do. Those fears appear to have abated somewhat. Reaching our 2028 target multiple of 13 times earnings could add 2.3% to annual returns over the next five years.

Cigna's dividend has largely not played a role in the company's total returns. That changed somewhat as Cigna's stock now offers a yield that is above the average yield of the S&P 500 index.

## Safety, Quality, Competitive Advantage, & Recession Resiliency

| Year   | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2028 |
|--------|------|------|------|------|------|------|------|------|------|------|------|------|
| Payout | 1%   | 1%   | 0%   | 0%   | 0%   | 0%   | 0%   | 0%   | 20%  | 19%  | 20%  | 16%  |


Cigna happens to operate in an industry that tends to hold up well during recessionary times as health insurance and pharmacy businesses are still in demand. Earnings-per-share fell from \$3.96 in 2007 to \$3.42 in 2008 (a 13.6% decrease), but rebounded to make a new high in 2009. Cigna has seen earnings-per-share grow each year thereafter outside of 2016.

We feel that Cigna has some immense competitive advantages. The company is one of the largest names in its industry, giving it a size and scale that is hard to match. Cigna's acquisition of Express Scripts appears to have been a solid move, strengthening the company's presence in its pharmacy business. Perhaps most important, an aging demographic will need increased pharmacy and medical services, giving Cigna an incredibly large pool of potential customers.

## Final Thoughts & Recommendation

Cigna is now expected to produce total returns of 13.7% through 2028, down from our prior estimate of 16.8%. Our projected return stems from a 10% earnings growth rate, a starting yield of 1.7%, and a low single-digit tailwind from multiple expansion. Cigna continues to produce solid growth rates, something we expect to continue in 2023. The company also raised its revenue guidance slightly following results. Shares earn a buy rating due to projected returns.

## Total Return Breakdown by Year



[Click here to rate and review this research report. Your feedback is important to us.](#)

Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



# Cigna Corporation (CI)

Updated August 7<sup>th</sup>, 2023 by Nathan Parsh

## Income Statement Metrics

| Year           | 2013  | 2014  | 2015  | 2016  | 2017  | 2018  | 2019   | 2020   | 2021   | 2022   |
|----------------|-------|-------|-------|-------|-------|-------|--------|--------|--------|--------|
| Revenue        | 32380 | 34914 | 37876 | 40007 | 42043 | 48569 | 153743 | 160577 | 174272 | 180021 |
| SG&A Exp.      |       |       |       | 9790  | 10030 | 11934 | 14053  | 14072  | 13030  | 13186  |
| Depr. & Amor.  | 597   | 588   | 585   | 610   | 566   | 695   | 3651   | 2802   | 2923   | 2937   |
| Net Profit     | 1476  | 2102  | 2094  | 1867  | 2237  | 2637  | 5104   | 8458   | 5365   | 6668   |
| Net Margin     | 4.6%  | 6.0%  | 5.5%  | 4.7%  | 5.3%  | 5.4%  | 3.3%   | 5.3%   | 3.1%   | 3.7%   |
| Free Cash Flow | 192   | 1685  | 2423  | 3565  | 3615  | 3242  | 8435   | 9256   | 6037   | 7361   |
| Income Tax     | 698   | 1210  | 1250  | 1136  | 1374  | 935   | 1450   | 2379   | 1367   | 1607   |

## Balance Sheet Metrics

| Year               | 2013  | 2014  | 2015  | 2016  | 2017  | 2018   | 2019   | 2020   | 2021   | 2022   |
|--------------------|-------|-------|-------|-------|-------|--------|--------|--------|--------|--------|
| Total Assets       | 54336 | 55870 | 57088 | 59360 | 61759 | 153226 | 155774 | 155451 | 154889 | 143932 |
| Cash & Equivalents | 2795  | 1420  | 1968  | 3185  | 2972  | 3855   | 4619   | 10182  | 5081   | 5924   |
| Acc. Receivable    | 9290  | 9837  | 10507 | 9555  | 8667  | 15704  | 16003  | 17199  | 19639  | 21713  |
| Goodwill & Int.    | 6931  | 6698  | 6587  | 6404  | 6509  | 83508  | 81164  | 79827  | 79913  | 78303  |
| Total Liabilities  | 43755 | 45081 | 45044 | 45633 | 48048 | 112191 | 110430 | 105123 | 107705 | 98981  |
| Accounts Payable   | 7506  | 8444  | 8848  | 8946  | 489   | 15068  | 15544  | 18825  | 6655   | 7775   |
| Long-Term Debt     | 5247  | 5126  | 5169  | 5032  | 5439  | 42478  | 37407  | 32919  | 33670  | 31093  |
| Total Equity       | 10567 | 10774 | 12035 | 13723 | 13711 | 41028  | 45338  | 50321  | 47112  | 44872  |
| LTD/E Ratio        | 0.50  | 0.48  | 0.43  | 0.37  | 0.40  | 1.04   | 0.83   | 0.65   | 0.71   | 0.69   |

## Profitability & Per Share Metrics

| Year             | 2013   | 2014   | 2015   | 2016   | 2017   | 2018   | 2019   | 2020   | 2021   | 2022   |
|------------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| Return on Assets | 2.7%   | 3.8%   | 3.7%   | 3.2%   | 3.7%   | 2.5%   | 3.3%   | 5.4%   | 3.5%   | 4.5%   |
| Return on Equity | 14.5%  | 19.7%  | 18.4%  | 14.5%  | 16.3%  | 9.6%   | 11.8%  | 17.7%  | 11.0%  | 14.5%  |
| ROIC             | 9.6%   | 13.2%  | 12.6%  | 10.4%  | 11.8%  | 5.1%   | 6.1%   | 10.2%  | 6.5%   | 8.5%   |
| Shares Out.      | 279    | 264    | 257    | 257    | 244    | 381    | 373    | 355    | 327    | 305    |
| Revenue/Share    | 113.74 | 129.98 | 145.35 | 154.08 | 164.83 | 196.91 | 408.98 | 439.96 | 515.66 | 575.03 |
| FCF/Share        | 0.67   | 6.27   | 9.30   | 13.73  | 14.17  | 13.14  | 22.44  | 25.36  | 17.86  | 23.51  |

Note: All figures in millions of U.S. Dollars unless per share or indicated otherwise.

### Disclaimer

Nothing presented herein is, or is intended to constitute, specific investment advice. Nothing in this research report should be construed as a recommendation to follow any investment strategy or allocation. Any forward-looking statements or forecasts are based on assumptions and actual results are expected to vary from any such statements or forecasts. No reliance should be placed on any such statements or forecasts when making any investment decision. While Sure Dividend has used reasonable efforts to obtain information from reliable sources, we make no representations or warranties as to the accuracy, reliability or completeness of third-party information presented herein. No guarantee of investment performance is being provided and no inference to the contrary should be made. There is a risk of loss from an investment in marketable securities. Past performance is not a guarantee of future performance.